GlassScriptPhysician profile
Michael P Underbrink
NPI 1609951383
$6,838.30
in general payments reported to CMS, 2019-2025
23 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 81% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $859 · 2021: $449 · 2022: $1,668 · 2023: $1,236 · 2024: $1,121 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,309.18 | 2022-2025 | Inspire |
| Optinose US, INC. | $896.54 | 2019-2020 | |
| Acclarent, INC | $884.01 | 2019-2024 | Acclarent Aera |
| Medical Device Business Services, INC. | $776.57 | 2022 | |
| Glaxosmithkline, LLC. | $541.70 | 2021-2024 | Nucala |
| Aerin Medical INC. | $465.96 | 2022-2025 | |
| Integra Lifesciences Corporation | $370.63 | 2024-2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Medtronic, INC. | $308.90 | 2022-2025 | Propel, Nuvent |
| Genzyme Corporation | $202.73 | 2024-2025 | |
| Zoll Respicardia, INC. | $179.86 | 2023 | Remede System |
| Regeneron Healthcare Solutions, INC. | $170.84 | 2021-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $144.45 | 2025 | Neffy |
| Grifols USA, LLC | $124.99 | 2025 | Xembify |
| Alk-Abello, INC | $118.19 | 2021 | |
| Itamar Medical INC | $113.99 | 2022-2023 | Watchpatone |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.82 | 2025 | Cuvitru |
| Astrazeneca Pharmaceuticals LP | $46.47 | 2025 | Tezspire |
| Baxter Healthcare | $32.50 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.14 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $18.91 | 2023 | |
| Checkpoint Surgical, INC | $18.81 | 2025 | Checkpoint Stimulators |
| Smith+Nephew, INC. | $17.94 | 2025 | Tula |
| Heron Therapeutics, INC. | $15.17 | 2025 | Aponvie |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Underbrink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.